AR060449A1 - Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1 - Google Patents

Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1

Info

Publication number
AR060449A1
AR060449A1 ARP070101582A ARP070101582A AR060449A1 AR 060449 A1 AR060449 A1 AR 060449A1 AR P070101582 A ARP070101582 A AR P070101582A AR P070101582 A ARP070101582 A AR P070101582A AR 060449 A1 AR060449 A1 AR 060449A1
Authority
AR
Argentina
Prior art keywords
seq
nucleotides
histamine
penultimate
region
Prior art date
Application number
ARP070101582A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR060449A1 publication Critical patent/AR060449A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee la interferencia de ARN para la inhibicion de la expresion de ARNm del receptor de histamina H1, en particular para tratar pacientes que padecen una afeccion relacionada con HRH1 (Receptor de Histamina H1) o en riesgo de desarrollar una afeccion relacionada con HRH1 tal como conjuntivitis alérgica, inflamacion ocular, dermatitis, rinitis, asma o alergia. Reivindicacion 1: El uso de ARN interferente para la fabricacion de un medicamento que atenua la expresion del ARNm del receptor de histamina H1 de un sujeto, que comprende: administrar al sujeto una composicion que comprende una cantidad efectiva de ARN interferente que tiene una longitud de 19 a 49 nucleotidos y un vehículo aceptable para uso farmacéutico, el ARN interferente que comprende un ARN seleccionado del grupo que consiste en: una region de por lo menos 13 nucleotidos contiguos que tiene por lo menos 90% de complementariedad de secuencia, o por lo menos 90% de identidad de secuencia con los penultimos 13 nucleotidos del extremo 3' del ARNm correspondiente a cualquiera de las SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 50; una region de por lo menos 14 nucleotidos contiguos que tiene por lo menos 85% de complementariedad de secuencia, o por lo menos 85% de identidad de secuencia, con los penultimos 14 nucleotidos del extremo 3' de un ARNm correspondiente a cualquiera de las SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 50; y una region de por lo menos 15, 16, 17 o 18 nucleotidos contiguos que tiene por lo menos 80% de complementariedad de secuencia, o por lo menos 80% de identidad de secuencia, con los penultimos 15, 16, 17 o 18 nucleotidos, respectivamente, del extremo 3' de un ARNm correspondiente a cualquiera de las SEC ID Ns 2 y SEC ID Ns 13 - SEC ID Ns 50; donde la expresion del ARNm del receptor de histamina H1 se atenua de este modo.
ARP070101582A 2006-04-13 2007-04-13 Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1 AR060449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79162306P 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
AR060449A1 true AR060449A1 (es) 2008-06-18

Family

ID=38610324

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101582A AR060449A1 (es) 2006-04-13 2007-04-13 Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1

Country Status (6)

Country Link
US (5) US8017592B2 (es)
EP (2) EP2003971A4 (es)
JP (1) JP5473594B2 (es)
AR (1) AR060449A1 (es)
TW (1) TW200808361A (es)
WO (1) WO2007121156A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2003971A4 (en) * 2006-04-13 2010-10-27 Alcon Res Ltd RNAI-mediated inhibition of status in association with the histamine receptor H1
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
CA3023867A1 (en) * 2016-05-09 2017-11-16 Biogaia Ab Selection of bacterial strains useful in allergy treatment
CN113604557A (zh) * 2021-08-04 2021-11-05 杭州浙大迪迅生物基因工程有限公司 一种人组胺受体HRH1 mRNA检测引物探针组、试剂盒和应用
US20240158856A1 (en) * 2021-08-04 2024-05-16 Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd Primer probe set for human histamine receptor hrh1 mrna detection, kit and detection method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
AU2004260009A1 (en) * 2003-07-11 2005-02-03 Oregon Health And Science University Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
JPWO2005028667A1 (ja) * 2003-09-19 2006-11-30 独立行政法人理化学研究所 ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
JPWO2005116204A1 (ja) * 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US20070213286A1 (en) * 2005-09-12 2007-09-13 The Trustees Of Columbia University In The City Of New York Inhibitors of dynein or lissencephaly 1, and methods of using same for treatment of neuronal disorders
EP2003971A4 (en) * 2006-04-13 2010-10-27 Alcon Res Ltd RNAI-mediated inhibition of status in association with the histamine receptor H1

Also Published As

Publication number Publication date
WO2007121156A8 (en) 2011-05-19
WO2007121156A2 (en) 2007-10-25
EP2003971A4 (en) 2010-10-27
JP5473594B2 (ja) 2014-04-16
US8222227B2 (en) 2012-07-17
JP2009533466A (ja) 2009-09-17
US20120264809A1 (en) 2012-10-18
EP2674493B1 (en) 2017-12-27
TW200808361A (en) 2008-02-16
US20140088172A1 (en) 2014-03-27
EP2674493A1 (en) 2013-12-18
US8017592B2 (en) 2011-09-13
US20090274631A1 (en) 2009-11-05
US20160053270A1 (en) 2016-02-25
US9206428B2 (en) 2015-12-08
WO2007121156A3 (en) 2008-11-06
US9745585B2 (en) 2017-08-29
US8618278B2 (en) 2013-12-31
US20110269822A1 (en) 2011-11-03
EP2003971A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
AR060448A1 (es) Inhibicion mediada por rnai de afecciones inflamatorias relacionadas con tirosina quinasa del bazo
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
JP2018533954A5 (es)
AR060449A1 (es) Inhibicion mediada por arni de afecciones relacionadas con el receptor de histamina h1
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
BRPI0912923A8 (pt) Composto que consiste de um oligonucleotídeo modificadpo composto de 12-30 nucleosídeos ligados, compostos que compreende um oligonucleotídeo modificado que compreende pelo menos 12 nucleosídeos ligados, composto que compreende um oligonucleotídeo modificado que compreende nucleosídeos ligados, e, uso de um composto
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
WO2009044392A3 (en) Novel sirna structures
WO2008050329A3 (en) Novel sirnas and methods of use thereof
AR083787A1 (es) Composicion farmaceutica que comprende un inhibidor del transportador 2 de sodio-glucosa (sglt2) y una insulina, procedimientos de tratamiento y usos de la misma
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BRPI0613859B8 (pt) inibidores da comt, seus usos, e composição farmacêutica
CL2007002274A1 (es) Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras.
BR112012011381B8 (pt) oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
WO2005091716A8 (en) Annexin ii and uses thereof
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR051848A1 (es) Inhibicion por arni de la amiloide a serica para el tratamiento del glaucoma
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
AR064016A1 (es) Inhibicion mediada por arni de acuaporina 4 para tratamiento de afecciones relacionadas con pio
WO2007128086A3 (en) Novel viral replication inhibitor
BRPI0710085B8 (pt) composições oftálmicas e seus kits
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
BRPI1006266A2 (pt) adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato

Legal Events

Date Code Title Description
FB Suspension of granting procedure